Journal article
Open-label, phase Ia study of STING agonist BI 1703880 plus ezabenlimab for patients with advanced solid tumors
- Abstract:
- BI 1703880, a novel STimulator of INterferon Genes (STING) agonist, has demonstrated preclinical antitumor activity. As STING activation can upregulate programmed death ligand 1 and human leukocyte antigen in tumor cells, a combination of BI 1703880 and an anti-programmed cell death protein 1-antibody, such as ezabenlimab, may improve efficacy. This first-in-human phase Ia study (NCT05471856) is evaluating BI 1703880 plus ezabenlimab in patients with advanced solid tumors. The study utilizes an innovative lead-in design; all patients receive BI 1703880 monotherapy in Cycle 1 and combination therapy from Cycle 2. The primary endpoint is dose-limiting toxicities during the maximum tolerated dose evaluation period. Results will inform the future development of BI 1703880 for treatment of metastatic or recurrent malignancies.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 864.4KB, Terms of use)
-
- Publisher copy:
- 10.1080/14796694.2024.2441107
Authors
+ Wellcome Trust
More from this funder
- Funder identifier:
- https://ror.org/029chgv08
- Grant:
- 224623/Z/21/Z
+ Cancer Research UK
More from this funder
- Funder identifier:
- https://ror.org/054225q67
- Grant:
- A25014
+ Boehringer Ingelheim Foundation
More from this funder
- Funder identifier:
- https://ror.org/03tx8dq56
- Publisher:
- Taylor and Francis
- Journal:
- Future Oncology More from this journal
- Volume:
- 21
- Issue:
- 2
- Pages:
- 195-200
- Place of publication:
- England
- Publication date:
- 2025-01-16
- Acceptance date:
- 2024-12-09
- DOI:
- EISSN:
-
1744-8301
- ISSN:
-
1479-6694
- Pmid:
-
39817655
- Language:
-
English
- Keywords:
- Pubs id:
-
2080187
- Local pid:
-
pubs:2080187
- Deposit date:
-
2025-03-24
- ARK identifier:
Terms of use
- Copyright holder:
- Harrington et al.
- Copyright date:
- 2025
- Rights statement:
- © 2025 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.
If you are the owner of this record, you can report an update to it here: Report update to this record